{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T16:56:54Z","timestamp":1775840214473,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40256-019-00391-z","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T03:02:32Z","timestamp":1576465352000},"page":"405-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Statins, LDL Cholesterol Control, Cardiovascular Disease Prevention, and Atherosclerosis Progression: A Clinical Perspective"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-6496","authenticated-orcid":false,"given":"Lorenzo","family":"Nesti","sequence":"first","affiliation":[]},{"given":"Alessandro","family":"Mengozzi","sequence":"additional","affiliation":[]},{"given":"Andrea","family":"Natali","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"issue":"9753","key":"391_CR1","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"8","key":"391_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrcardio.2013.80","volume":"10","author":"Z Reiner","year":"2013","unstructured":"Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013;10(8):453\u201364.","journal-title":"Nat Rev Cardiol."},{"issue":"5","key":"391_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","volume":"64","author":"SM Boekholdt","year":"2014","unstructured":"Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5):485\u201394.","journal-title":"J Am Coll Cardiol."},{"issue":"39","key":"391_CR4","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999\u20133058.","journal-title":"Eur Heart J."},{"issue":"25 Pt B","key":"391_CR5","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889\u2013934.","journal-title":"J Am Coll Cardiol"},{"key":"391_CR6","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018.","DOI":"10.1161\/CIR.0000000000000624"},{"issue":"Suppl 1","key":"391_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2165\/1153644-S0-000000000-00000","volume":"10","author":"M Marzilli","year":"2010","unstructured":"Marzilli M. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs. 2010;10(Suppl 1):3\u20139.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"9","key":"391_CR8","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.clinthera.2004.09.006","volume":"26","author":"PH Jones","year":"2004","unstructured":"Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004;26(9):1388\u201399.","journal-title":"Clin Ther."},{"issue":"7","key":"391_CR9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1056\/NEJM199908123410707","volume":"341","author":"RH Knopp","year":"1999","unstructured":"Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341(7):498\u2013511.","journal-title":"N Engl J Med."},{"issue":"5","key":"391_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0002-9149(02)02229-4","volume":"89","author":"EA Stein","year":"2002","unstructured":"Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol. 2002;89(5):50\u20137.","journal-title":"Am J Cardiol."},{"issue":"1","key":"391_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","volume":"105","author":"SJ Nicholls","year":"2010","unstructured":"Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105(1):69\u201376.","journal-title":"Am J Cardiol."},{"issue":"5A","key":"391_CR12","doi-asserted-by":"publisher","first-page":"28B","DOI":"10.1016\/S0002-9149(01)01454-0","volume":"87","author":"F McTaggart","year":"2001","unstructured":"McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87(5A):28B\u201332B.","journal-title":"Am J Cardiol."},{"issue":"17","key":"391_CR13","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","volume":"37","author":"PM Ridker","year":"2016","unstructured":"Ridker PM, Mora S, Rose L, Group JTS. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016;37(17):1373\u20139.","journal-title":"Eur Heart J."},{"key":"391_CR14","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1038\/ncomms6068","volume":"5","author":"I Postmus","year":"2014","unstructured":"Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014;5:5068.","journal-title":"Nat Commun."},{"issue":"2","key":"391_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0021-9150(95)05571-D","volume":"117","author":"F Pazzucconi","year":"1995","unstructured":"Pazzucconi F, Dorigotti F, Gianfranceschi G, Campagnoli G, Sirtori M, Franceschini G, et al. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. Atherosclerosis. 1995;117(2):189\u201398.","journal-title":"Atherosclerosis."},{"issue":"10","key":"391_CR16","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","volume":"24","author":"Z Reiner","year":"2014","unstructured":"Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24(10):1057\u201366.","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"4","key":"391_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00228-015-1994-9","volume":"72","author":"S Trompet","year":"2016","unstructured":"Trompet S, Postmus I, Slagboom PE, Heijmans BT, Smit RA, Maier AB, et al. Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies. Eur J Clin Pharmacol. 2016;72(4):431\u20137.","journal-title":"Eur J Clin Pharmacol."},{"issue":"9","key":"391_CR18","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1345\/aph.1M571","volume":"44","author":"EK Reindl","year":"2010","unstructured":"Reindl EK, Wright BM, Wargo KA. Alternate-day statin therapy for the treatment of hyperlipidemia. Ann Pharmacother. 2010;44(9):1459\u201370.","journal-title":"Ann Pharmacother."},{"issue":"3","key":"391_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1345\/aph.1K604","volume":"42","author":"JM Backes","year":"2008","unstructured":"Backes JM, Venero CV, Gibson CA, Ruisinger JF, Howard PA, Thompson PD, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother. 2008;42(3):341\u20136.","journal-title":"Ann Pharmacother."},{"issue":"9841","key":"391_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"J Emberson","year":"2012","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators MB, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u201390.","journal-title":"Lancet"},{"issue":"25","key":"391_CR21","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med."},{"issue":"12","key":"391_CR22","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289\u201397.","journal-title":"JAMA."},{"issue":"18","key":"391_CR23","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med."},{"issue":"22","key":"391_CR24","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med."},{"issue":"252","key":"391_CR25","first-page":"207","volume":"2016","author":"Task Force Authors","year":"2016","unstructured":"Authors Task Force, Members Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, et al. European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;2016(252):207\u201374.","journal-title":"Atherosclerosis."},{"issue":"9364","key":"391_CR26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahl\u00f6f B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149\u201358.","journal-title":"Lancet"},{"issue":"32","key":"391_CR27","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"9","key":"391_CR28","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071\u201380.","journal-title":"JAMA."},{"issue":"22","key":"391_CR29","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","volume":"365","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078\u201387.","journal-title":"N Engl J Med."},{"issue":"5","key":"391_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","volume":"66","author":"K Tsujita","year":"2015","unstructured":"Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66(5):495\u2013507.","journal-title":"J Am Coll Cardiol."},{"issue":"22","key":"391_CR31","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373\u201384.","journal-title":"JAMA."},{"issue":"3","key":"391_CR32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/joim.12359","volume":"278","author":"AC Shore","year":"2015","unstructured":"Shore AC, Colhoun HM, Natali A, Palombo C, Ostling G, Aizawa K, et al. Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study. J Intern Med. 2015;278(3):291\u2013302.","journal-title":"J Intern Med."},{"key":"391_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12916-015-0459-4","volume":"13","author":"M Banach","year":"2015","unstructured":"Banach M, Serban C, Sahebkar A, Mikhailidis DP, Ursoniu S, Ray KK, et al. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med. 2015;13:229.","journal-title":"BMC Med."},{"issue":"9","key":"391_CR34","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.amjcard.2009.12.049","volume":"105","author":"D Shiffman","year":"2010","unstructured":"Shiffman D, Sabatine MS, Louie JZ, Kirchgessner TG, Iakoubova OA, Campos H, et al. Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. Am J Cardiol. 2010;105(9):1300\u20135.","journal-title":"Am J Cardiol."},{"issue":"6","key":"391_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/qjmed\/95.6.397","volume":"95","author":"U Ravnskov","year":"2002","unstructured":"Ravnskov U. Is atherosclerosis caused by high cholesterol? QJM. 2002;95(6):397\u2013403.","journal-title":"QJM."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00391-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-019-00391-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00391-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T14:23:04Z","timestamp":1665238984000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-019-00391-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["391"],"URL":"https:\/\/doi.org\/10.1007\/s40256-019-00391-z","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,16]]},"assertion":[{"value":"16 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Lorenzo Nesti, Alessandro Mengozzi, and Andrea Natali have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}